Cipla climbs 3% on USFDA approval to HIV drug

NEW DELHI: Shares of Cipla climbed over 3 per cent in Wednesday's trade after the drug maker informed stock exchanges that it has received final approval from USFDA for an HIV treatment drug Efavirenz.

The drug will be the generic therapeutic equivalent version of Bristol-Myers Squibb Pharma Company’s, Sustiva.

According to IQVIA (IMS Health), Sustiva and its generic equivalents had US sales of approximately $105M for the 12-month period ending April 2018. The product is available for shipping immediately.


The company has received final approval for its abbreviated new drug application (ANDA) for Efavirenz tablets 600mg from the (USFDA) United States Food and Drug Administration.

The stock rose 3.27 per cent to hit a high of Rs 622 on BSE.

Efavirenz tablets are AB-rated generic therapeutic equivalent version of Bristol-Myers Squibb Pharma Company’s, Sustiva.

It is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg, the company said.